AgomAb Therapeutics (NASDAQ:AGMB) Shares Down 4.5% – Here’s What Happened

AgomAb Therapeutics NV (NASDAQ:AGMB) shares dropped 4.5% during trading on Wednesday . The stock traded as low as $15.14 and last traded at $15.19. Approximately 64,273 shares changed hands during trading, a decline of 64% from the average daily volume of 177,089 shares. The stock had previously closed at $15.90.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Leerink Partners initiated coverage on shares of AgomAb Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $36.00 price target for the company. Morgan Stanley assumed coverage on shares of AgomAb Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $28.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on AgomAb Therapeutics in a report on Tuesday. They set an “overweight” rating and a $32.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $32.00.

AgomAb Therapeutics Price Performance

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.